FDA Approves New Non-Hormonal Drug for Menopause Relief

🧾 In Brief

Women experiencing hot flashes, night sweats, and disrupted sleep during menopause finally have a new option — without hormones. The U.S. Food and Drug Administration (FDA) has approved fezolinetant (brand name Veozah), a first-in-class, non-hormonal treatment designed to reduce the frequency and severity of vasomotor symptoms (VMS) — the medical term for hot flashes and night sweats.

Unlike traditional hormone replacement therapy (HRT), which raises oestrogen levels, Veozah targets the brain’s temperature-regulating pathway to bring balance naturally. It’s being described as a “game changer” for millions of women who can’t or choose not to take hormones.

🌍 Why It Matters

For decades, hormone therapy has been the gold standard for managing menopause symptoms — but it’s not suitable for everyone. Women with a history of breast cancer, heart disease, or blood clots often can’t use HRT safely.

That’s where Veozah steps in. It works by blocking neurokinin 3 (NK3) receptors in the brain’s hypothalamus — the area that helps regulate body temperature. During menopause, fluctuating oestrogen levels overstimulate this region, causing sudden heat surges and night sweats. By calming this signal, fezolinetant reduces hot flashes by more than 60% in clinical trials, improving both comfort and sleep quality.

Experts say this marks the first major innovation in menopause care in over 20 years, offering women a new path to symptom relief — without relying on hormones.

💡 What You Can Do

💬 Talk to your doctor: Ask if Veozah or upcoming similar non-hormonal drugs (like Elinzanetant, currently in trials) may be right for you.
🩺 Monitor your liver health: The FDA recommends periodic liver function tests while using Veozah, as mild enzyme changes were noted in some participants.
🌿 Combine with lifestyle changes: A balanced diet, regular exercise, hydration, and mindfulness-based stress reduction can further ease menopausal discomfort.
💤 Prioritise sleep: Many users report improved sleep after hot flashes subside — making rest and relaxation key parts of recovery.

🔍 The Bigger Picture

Globally, over 1 billion women are expected to experience menopause by 2030 — yet the conversation around treatment remains stigmatised and underfunded. The approval of Veozah signals a cultural and scientific shift: recognising menopause as a legitimate health priority, not just “a phase.”

Beyond drugs, the movement for menopause-friendly workplaces, open conversations, and holistic support is growing. From nutrition to mental health, women’s midlife wellness is finally getting the attention it deserves.

💬 What’s Your Take?

Would you try a non-hormonal option like Veozah for menopause relief?
👇 Share your thoughts or tag @TheHealthizans — let’s make menopause conversations open and empowering!

📚 Sources